PATH-SCAN: A REPORTING TOOL FOR IDENTIFYING CLINICALLY ACTIONABLE VARIANTS

被引:0
|
作者
Daneshjou, Roxana [1 ]
Zappala, Zachary [1 ]
Kukurba, Kim [1 ]
Boyle, Sean M. [1 ]
Ormond, Kelly E. [1 ]
Klein, Teri E. [1 ]
Snyder, Michael [1 ]
Bustamante, Carlos D. [1 ]
Altman, Russ B. [1 ,2 ]
Montgomery, Stephen B. [1 ,3 ]
机构
[1] Stanford Univ, Dept Genet, Stanford, CA 94061 USA
[2] Stanford Univ, Dept Bioengn, Stanford, CA 94061 USA
[3] Stanford Univ, Dept Pathol, Stanford, CA 94061 USA
关键词
POLYMORPHISM H558R; SPLICE VARIANT; SCN5A; ASSOCIATION; EXPRESSION;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The American College of Medical Genetics and Genomics (ACMG) recently released guidelines regarding the reporting of incidental findings in sequencing data. Given the availability of Direct to Consumer (DTC) genetic testing and the falling cost of whole exome and genome sequencing, individuals will increasingly have the opportunity to analyze their own genomic data. We have developed a web-based tool, PATH-SCAN, which annotates individual genomes and exomes for ClinVar designated pathogenic variants found within the genes from the ACMG guidelines. Because mutations in these genes predispose individuals to conditions with actionable outcomes, our tool will allow individuals or researchers to identify potential risk variants in order to consult physicians or genetic counselors for further evaluation. Moreover, our tool allows individuals to anonymously submit their pathogenic burden, so that we can crowd source the collection of quantitative information regarding the frequency of these variants. We tested our tool on 1092 publicly available genomes from the 1000 Genomes project, 163 genomes from the Personal Genome Project, and 15 genomes from a clinical genome sequencing research project. Excluding the most commonly seen variant in 1000 Genomes, about 20% of all genomes analyzed had a ClinVar designated pathogenic variant that required further evaluation.
引用
收藏
页码:229 / 240
页数:12
相关论文
共 50 条
  • [21] Analytical performance of a new liquid biopsy mutation panel for detection of clinically actionable variants
    Svedman, C.
    Alexander, G.
    Bergamaschi, A.
    Han, J.
    Harrington, P. B.
    Ku, C-J.
    Ma, Y.
    Gibb, W.
    Rossi, A. Dei
    Shen, L.
    Goddard, A. D.
    Eberhard, D. A.
    Clark-Langone, K. M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC)
    Hahn, A. W.
    Kapron, A. L.
    Boyle, J.
    Kohlmann, W.
    Poole, A.
    Gill, D. M.
    Greenberg, S.
    Hale, P.
    Teerlink, C.
    Maughan, B. L.
    Cannon-Albright, L.
    Agarwal, N.
    Cooney, K. A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows
    Turki M. Sobahy
    Ghassan Tashkandi
    Donya Bahussain
    Raneem Al-Harbi
    BMC Medical Genomics, 15
  • [24] Evaluation of the Qiagen GeneReader NGS System for the Detection and Reporting of Clinically Actionable Mutations in Solid Tumors
    Turner, S. A.
    Jung, H. S.
    de Abreu, F. B.
    Peterson, J. D.
    Tsongalis, G. J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (06): : 1034 - 1034
  • [25] Identifying Clinically Actionable Alterations in the Era of P4plus Medicine: Challenges and Opportunities
    Shen, B.
    PANCREAS, 2018, 47 (05) : 527 - 527
  • [26] A Screening Approach to Identify Clinically Actionable Variants Causing Congenital Heart Disease in Exome Data
    Szot, Justin O.
    Cuny, Hartmut
    Blue, Gillian M.
    Humphreys, David T.
    Ip, Eddie
    Harrison, Katrina
    Sholler, Gary F.
    Giannoulatou, Eleni
    Leo, Paul
    Duncan, Emma L.
    Sparrow, Duncan B.
    Ho, Joshua W. K.
    Graham, Robert M.
    Pachter, Nicholas
    Chapman, Gavin
    Winlaw, David S.
    Dunwoodie, Sally L.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2018, 11 (03): : e001978
  • [27] DeMAG predicts the effects of variants in clinically actionable genes by integrating structural and evolutionary epistatic features
    Federica Luppino
    Ivan A. Adzhubei
    Christopher A. Cassa
    Agnes Toth-Petroczy
    Nature Communications, 14
  • [28] DeMAG predicts the effects of variants in clinically actionable genes by integrating structural and evolutionary epistatic features
    Luppino, Federica
    Adzhubei, Ivan A.
    Cassa, Christopher A.
    Toth-Petroczy, Agnes
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [29] Identification of clinically actionable pharmacogenetic variants during tumor genetic profiling in pediatric cancer patients
    Hertz, Daniel Louis
    Robinson, Dan R.
    Lonigro, Robert J.
    Wu, Yi-Mi
    Vats, Pankaj
    Cao, Xuhong
    Nobani, Andrew
    Mora, Erika
    Chinnaiyan, Arul M.
    Mody, Rajen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Performance of next-generation sequencing for detection of clinically actionable genetic variants in cancer.
    Hussaini, Mohammed Omar
    Hagemann, Ian S.
    Cox, Teresa Mary
    Lockwood, Christina
    Seibert, Karen
    Kulkarni, Shashikant
    Pfeifer, John
    Duncavage, Eric James
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)